Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Eva Herweijer, Amy Leval, Alexander Ploner, Sandra Eloranta, Julia Fridman Simard, Joakim Dillner, Eva Netterlid, Pär Sparén, Lisen Arnheim-Dahlström

Research output: Contribution to journalArticlepeer-review

66 Citations (SciVal)

Abstract

Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
Original languageEnglish
Pages (from-to)597-603
JournalJAMA: The Journal of the American Medical Association
Volume311
Issue number6
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Environmental Health and Occupational Health
  • Dermatology and Venereal Diseases

Keywords

  • Condylomata Acuminata: epidemiology
  • Condylomata Acuminata: prevention & control
  • Papillomavirus Infections: prevention & control
  • Papillomavirus Vaccines: administration & dosage
  • Registries: statistics & numerical data
  • Sweden: epidemiology
  • Uterine Cervical Neoplasms: prevention & control
  • Vaccination: statistics & numerical data

Fingerprint

Dive into the research topics of 'Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.'. Together they form a unique fingerprint.

Cite this